Boxer Gut Health: The Bacteria That Invades Their Gut Wall

Summary

Boxer gut health is defined by one of the most clinically specific gastrointestinal conditions in veterinary medicine: histiocytic ulcerative colitis (HUC), also known as granulomatous colitis, caused by adherent-invasive Escherichia coli (AIEC) that penetrate the colonic mucosa and trigger a macrophage-dominated inflammatory cascade. The discovery that this condition was bacterial rather than purely immune-mediated transformed both diagnosis and treatment, with targeted fluoroquinolone therapy producing dramatic clinical remission in susceptible dogs. Beyond HUC, Boxers carry a significant predisposition to mast cell tumours and brain tumours, making gut-immune axis support a long-term priority. This article examines the scientific evidence for Boxer gut vulnerability, the mechanisms linking microbiome health to mucosal defence and immune surveillance, and the practical steps Boxer owners can take to support their dog’s gut health at every life stage.

---

Introduction

The Boxer is a breed built for resilience. Athletic, loyal, and intensely bonded to their families, they are also one of the most medically distinctive dogs in veterinary practice. While much of the attention given to Boxer health focuses on heart conditions and cancer risk, it is the gut that holds some of the most scientifically revealing clues to the Boxer’s long-term wellbeing. No other breed is as closely associated with histiocytic ulcerative colitis, a severe inflammatory bowel condition whose underlying cause, once uncovered, turned out to be a bacteria-driven mucosal invasion rather than the primary immune disorder it had been mistaken for across decades of veterinary practice.

Understanding Boxer gut health means understanding the relationship between the colonic microbiome and the mucosal immune system. In Boxers, this relationship is not simply a background health consideration; it operates closer to a clinical fault line. The same immune architecture that makes the Boxer susceptible to AIEC-driven colitis also intersects with the breed’s broader predisposition to immune-mediated and neoplastic disease. A compromised or dysbiotic gut microbiome creates conditions that are unfavourable not just for the gut itself, but for the systemic immune function the gut underpins.

This article covers the full picture of Boxer gut health: the primary clinical condition that defines the breed’s gastrointestinal profile, the broader enteropathy and digestive sensitivity patterns that affect day-to-day life, and the cancer-longevity argument for treating consistent microbiome support as a strategic health investment across the Boxer’s lifespan.

---

Key Takeaways

• Histiocytic ulcerative colitis (HUC) is the defining gut condition in Boxers, caused by adherent-invasive Escherichia coli (AIEC) that invade the colonic mucosa and drive granulomatous inflammation.
• The discovery of AIEC as the cause of HUC was a paradigm shift in veterinary gastroenterology: this condition was previously treated with immunosuppression and carried a poor prognosis; targeted antibiotic therapy now produces remission in the majority of cases.
• HUC typically presents in young Boxers under four years of age and is characterised by bloody, mucoid diarrhoea, weight loss, hypoalbuminaemia, and anaemia in severe cases.
• Boxers carry a documented predisposition to mast cell tumours and brain tumours, making gut-immune axis and gut-longevity axis support a meaningful long-term priority for owners.
• General gastrointestinal sensitivity, including food reactivity, flatulence, and bloat risk, is widely reported in Boxers and should be managed proactively through diet and microbiome support.
• A diverse, well-supported gut microbiome may help maintain the mucosal barrier integrity that limits AIEC colonisation and supports the systemic immune surveillance relevant to the Boxer’s cancer predisposition.

---

In This Guide:

• The Gut Health Profile of the Boxer
• Histiocytic Ulcerative Colitis in Boxers: The AIEC Connection
• Chronic Enteropathy and the Gut-Immune Axis in Boxers
• Food Sensitivity, Flatulence, and Digestive Sensitivity in Boxers
• Cancer Predisposition, Immune Surveillance, and the Gut-Longevity Axis
• Boxer Gut Dysbiosis: What the Research Shows
• How Bonza Supports Boxer Gut Health
• How To Support Your Boxer’s Gut Health: A Practical Guide
• Safety Considerations and When to See Your Vet
• Frequently Asked Questions
• Conclusion
• Related Articles
• References
• Editorial Information

---

The Gut Health Profile of the Boxer

Boxer gut health cannot be approached as a generic breed topic. Three converging factors give the Boxer a gastrointestinal profile that is more clinically specific, and more consequential, than most breeds.

The first and most defining is histiocytic ulcerative colitis, a severe colonic condition with a unique bacterial pathogenesis documented almost exclusively in Boxers and, to a lesser extent, French Bulldogs. This is not a variant of generic inflammatory bowel disease. It is a bacteria-driven mucosal pathology with a specific causative organism, a specific mechanism of injury, and a specific treatment response that differentiates it sharply from other forms of canine chronic enteropathy.¹

The second factor is a pronounced predisposition to cancer, particularly mast cell tumours and brain tumours. The Boxer carries the highest breed-specific prevalence of mast cell tumours of any breed in England based on primary-care data, with a prevalence of 1.95% compared to the all-breed average of 0.27%.⁸ This cancer burden is relevant to gut health because the gut-associated lymphoid tissue (GALT) constitutes one of the body’s largest immune organs, and a well-supported gut microbiome is integral to systemic immune surveillance.

The third factor is a general predisposition to gastrointestinal sensitivity, widely reported by Boxer owners and veterinary practitioners, encompassing food reactivity, flatulence, soft stools, and susceptibility to bloat. This sensitivity likely reflects the Boxer’s immune reactivity at the gut wall and, in some cases, their brachycephalic-adjacent skull anatomy, which can affect air swallowing and gastrointestinal transit.

Taken together, these three factors make gut health a priority concern in Boxers across every stage of life.

---

Histiocytic Ulcerative Colitis in Boxers: The AIEC Connection

What HUC Is and Why It Matters

Histiocytic ulcerative colitis, also described as granulomatous colitis or HUC, was first documented in Boxer dogs in 1965. For several decades it was classified as an idiopathic immune-mediated condition, treated with immunosuppression, and associated with a guarded to poor prognosis. Clinical outcomes were frequently unsatisfactory, and the disease was understood as an aberrant overreaction by the Boxer’s own immune system.¹

That understanding changed fundamentally with the work of Simpson, Dogan, and colleagues, whose 2006 study demonstrated that granulomatous colitis in Boxers was not primarily immune-mediated but bacterially driven. Using fluorescence in situ hybridisation (FISH), the research team identified selective, multifocal intramucosal colonisation by Escherichia coli in 100% of affected tissue samples, absent in controls. The isolated strains shared phenotypic characteristics with adherent-invasive Escherichia coli (AIEC) previously associated with Crohn’s disease in humans: they adhered to and invaded cultured colonic epithelial cells, persisted within macrophages, and displayed virulence gene profiles consistent with extraintestinal pathogenic E. coli.¹

This was a major paradigm shift. The condition previously attributed to a disordered immune response was, in fact, the immune system’s response to a real mucosal invader; the problem was not immune overactivity in isolation, but an inability to effectively clear bacteria that had established themselves within the colonic mucosa and inside macrophages.

The Mechanism of Injury

The sequence of events in HUC begins with AIEC penetrating the colonic epithelium. Unlike commensal bacteria that reside in the intestinal lumen or superficial mucus layer, AIEC adhere to enterocytes, trigger their own internalisation, and transit into the lamina propria. Once there, they are taken up by macrophages but, critically, resist intracellular killing. They replicate within macrophages rather than being destroyed by them.¹

This failure of macrophage bactericidal activity drives the characteristic histological picture of HUC: dense accumulation of large, foamy, periodic acid-Schiff (PAS)-positive macrophages in the colonic mucosa and submucosa, accompanied by loss of colonic glands, goblet cell depletion, and mucosal ulceration. The macrophages are pro-inflammatory in phenotype, with upregulation of lysozyme and L1 antigen and reduced expression of CD163, the anti-inflammatory macrophage marker seen in healthy colonic tissue.³

Genetically, susceptibility in Boxers and French Bulldogs has been linked to a region on chromosome 38 encoding the CD48/SLAM family of genes, which play a role in macrophage-mediated sensing and killing of intracellular E. coli. This genetic architecture is analogous to loci implicated in human inflammatory bowel disease, reinforcing the view that canine HUC is a genuine disease model for the human AIEC-Crohn’s disease axis.⁵

The Enrofloxacin Treatment Shift

The breakthrough in treatment came with the recognition that targeted fluoroquinolone therapy could eradicate intramucosal E. coli and produce durable clinical and histological remission. Mansfield and colleagues demonstrated prospectively that clinical remission in Boxers treated with enrofloxacin correlated directly with eradication of intramucosal bacteria as confirmed on repeat biopsy and FISH analysis. Dogs achieving bacterial eradication recovered; those retaining intramucosal E. coli did not.² This was one of the clearest examples in veterinary medicine of a targeted antimicrobial resolving what had previously been managed, poorly, with immunosuppression.

The same pattern was subsequently confirmed in French Bulldogs, where fluoroquinolone treatment induced lasting clinical remission across a median follow-up period of up to 30 months.⁴

The Problem of Antimicrobial Resistance

The treatment picture is complicated by the emergence of fluoroquinolone-resistant and multidrug-resistant (MDR) AIEC strains. A 2021 study of 20 Boxers and four French Bulldogs with confirmed GC found fluoroquinolone-resistant E. coli at initial biopsy in 15 of 24 dogs, with susceptibility of MDR strains restricted to carbapenems in the majority of resistant cases. Treatment guided by antimicrobial susceptibility profiling was associated with positive long-term outcomes in over 80% of cases overall, but resistance significantly compromised outcomes in affected dogs.⁶ This underlines the importance of colonic biopsy and susceptibility testing at diagnosis rather than empirical fluoroquinolone prescription.

Diagnosis of HUC currently relies on colonoscopy with biopsy, histopathology showing the characteristic PAS-positive macrophage infiltrate, and confirmation of intramucosal E. coli via FISH or immunohistochemistry. A 2024 study confirmed that in situ hybridisation (ISH) is a specific and accessible alternative to FISH for confirming mucosal E. coli in suspected cases.⁷

Clinical Presentation and Prognosis

HUC typically affects young Boxers under four years of age. The clinical signs are those of large-bowel diarrhoea: increased frequency of defecation, mucoid and bloody stools, tenesmus, and haematochezia. Severe or prolonged disease produces weight loss, hypoalbuminaemia, and anaemia. Endoscopically, the colonic mucosa appears diffusely thickened, ulcerated, and hyperaemic.³

With appropriate diagnosis and treatment, particularly in fluoroquinolone-sensitive cases, prognosis has improved substantially from the historically guarded outlook of the pre-AIEC era. In resistant cases, outcomes remain more variable and require targeted therapy based on susceptibility profiling.

---

Chronic Enteropathy and the Gut-Immune Axis in Boxers

Beyond HUC, Boxers may present with other forms of chronic enteropathy, including food-responsive diarrhoea and antibiotic-responsive diarrhoea that do not involve the PAS-positive macrophage infiltrate characteristic of granulomatous colitis. These conditions share the same dysbiosis landscape common to chronic enteropathies across breeds: reduced microbial diversity, depletion of beneficial commensal populations such as Faecalibacterium and Clostridium hiranonis, and shifts in the short-chain fatty acid profile that impair mucosal barrier function and fuel inflammatory signalling.¹⁰

The gut-immune axis is the central conceptual framework for understanding the Boxer’s gut health risk profile. The gut-associated lymphoid tissue represents the largest concentration of immune tissue in the body, and its function is intimately dependent on the composition and diversity of the gut microbiome. A balanced, diverse microbiome promotes regulatory T cell development, modulates the Th1/Th2/Th17 immune balance, and maintains mucosal barrier integrity, all of which limit opportunities for pathogenic bacterial colonisation. A disrupted or low-diversity microbiome does the opposite: it weakens the mucosal barrier, creates ecological niches that favour pathobionts, and tips immune signalling towards chronic inflammation.

For Boxers, this matters on multiple levels. The same mucosal immune architecture that fails to contain AIEC in HUC-susceptible dogs is also the primary barrier preventing AIEC colonisation in the first place. A healthy, diverse gut microbiome supports the colonisation resistance that makes mucosal invasion by opportunistic pathogens less likely. The gut-immune axis in Boxers is therefore not just a therapeutic target for managing established disease; it is a preventive priority for reducing the conditions under which HUC can establish itself.

Bonza’s pillar article on the Gut-Immune Axis in Dogs: How Gut Health Supports Immune Health provides a full exploration of these mechanisms.

---

Food Sensitivity, Flatulence, and Digestive Sensitivity in Boxers

Alongside the specific clinical risk of HUC, Boxers as a breed are widely recognised for a generalised gastrointestinal sensitivity. Food reactivity, loose stools, flatulence, and a tendency towards bloating are frequently reported in clinical practice and by owners. While breed-specific controlled studies on adverse food reactions in Boxers are limited, the pattern is consistent with the Boxer’s immune reactivity at the gut wall and their anatomical characteristics.

Boxers have a degree of brachycephalic anatomy, including a shortened facial structure and, in some dogs, altered swallowing mechanics. This can contribute to increased air swallowing and gastrointestinal gas production. Their deep chest conformation also creates structural predisposition to gastric dilatation, making bloat a health risk that should be taken seriously with feeding management: smaller meals, avoidance of exercise immediately after eating, and avoiding highly fermentable ingredients likely to drive rapid gas production.

The immune reactivity component of food sensitivity in Boxers may reflect the same heightened mucosal immune state that characterises the breed’s predisposition to HUC. When the gut-immune axis is already operating under elevated tension, dietary antigens are more likely to trigger inflammatory responses. Highly digestible, ingredient-consistent diets that minimise the antigen load on the intestinal immune system are an important management tool for Boxers with a history of digestive sensitivity.

---

Cancer Predisposition, Immune Surveillance, and the Gut-Longevity Axis

Boxers carry one of the most substantial cancer burdens of any breed in veterinary epidemiology. The Boxer’s predisposition to mast cell tumours is among the most consistently documented in the literature. VetCompass data from England found the Boxer had the highest breed-specific MCT prevalence at 1.95%, compared to an overall population prevalence of 0.27%.⁸ Breed-predispositions research confirms that the Boxer is predisposed to both mast cell tumours and brain tumours, a dual neoplastic burden that reflects an underlying genetic vulnerability rather than coincidence.⁹

This matters for gut health in a specific and scientifically defensible way. The gut microbiome is not merely a digestive organ; it is an active participant in systemic immune regulation. Gut-associated lymphoid tissue processes approximately 70% of the body’s immune activity, and the microbiome directly shapes the immune cell populations, cytokine profiles, and tumour surveillance mechanisms that the body deploys against neoplastic cells. Research in both human and veterinary oncology increasingly points to microbiome diversity as a factor influencing the immune system’s ability to identify and respond to early-stage neoplastic change.

For Boxer owners, this creates a meaningful frame for thinking about gut health investment. The question is not simply whether a Boxer’s digestion appears normal from day to day, but whether the microbiome is sufficiently diverse and robust to sustain the systemic immune surveillance that matters most in a breed carrying elevated cancer risk. A low-diversity or dysbiotic gut microbiome creates chronic, low-grade immune activation that consumes regulatory bandwidth, depresses natural killer cell activity, and reduces the responsiveness of the immune system to new threats.

Maintaining a healthy gut microbiome is not a guaranteed cancer preventive strategy, and it should not be framed as one. However, the scientific case for gut health as a contributor to immune resilience and healthspan in cancer-predisposed breeds is well-supported and grows stronger with each year of research in this field. Bonza’s Gut-Longevity Axis in Dogs: Key To Improved Healthspan covers this mechanism in full.

---

Boxer Gut Dysbiosis: What the Research Shows

Dogs with chronic enteropathies, including granulomatous colitis, show microbiome profiles that differ systematically from healthy controls. The pattern is consistent with what is observed across canine inflammatory bowel conditions: reduced species richness, reduced microbial diversity, depletion of Faecalibacterium and other key butyrate producers, shifts in the Firmicutes-to-Proteobacteria ratio, and impairment of short-chain fatty acid metabolism.¹⁰

Short-chain fatty acids, particularly butyrate, are essential for colonocyte energy metabolism, mucosal barrier maintenance, and anti-inflammatory signalling in the colonic epithelium. When microbial diversity falls and butyrate-producing populations decline, colonocytes receive less of the nutritional and signalling support they need, tight junction integrity weakens, and the mucosal barrier becomes more permeable to luminal bacteria. For a breed where the defining disease risk is precisely mucosal invasion by a resident E. coli pathobiont, this matters more than in most.

The relationship between dysbiosis and HUC risk in Boxers is not a simple one-way street. Established HUC itself drives further dysbiosis, and the inflammatory environment of the colon in active HUC promotes the growth of pathobiont species over commensals. This creates the self-perpetuating cycle common to inflammatory gut disease: dysbiosis facilitates mucosal invasion, mucosal invasion drives inflammation, and inflammation deepens dysbiosis. Understanding this cycle reinforces the case for proactive microbiome support rather than waiting for clinical disease to establish itself.

Emerging research also implicates the CD48/SLAM genetic locus in Boxer and French Bulldog GC susceptibility in ways that interact with macrophage function and bacterial killing. Dogs carrying risk haplotypes in this region demonstrate impaired ability to clear AIEC from within macrophages compared to controls.⁵ This genetic vulnerability is present from birth; the microbiome is a modifiable variable that can either mitigate or compound it.

---

How Bonza Supports Boxer Gut Health

Biotics: The Foundation for Every Boxer

For Boxers, Biotics is not an optional supplement. It is the non-negotiable microbiome foundation for a breed whose defining disease risk is rooted in mucosal colonisation by an invasive bacterial pathobiont.

Postbiotics for Dogs: Evidence-Based Guide to Health BenefitsBiotics delivers the full Biotics Triad: prebiotics to selectively nourish beneficial microbial populations, the Calsporin® probiotic strain (Bacillus velezensis DSM 15544) as the sole live probiotic to support microbial diversity and colonisation resistance, and postbiotics, including TruPet™ and Lactobacillus helveticus HA-122, to deliver the bioactive microbial metabolites that support mucosal barrier integrity and gut-associated immune function directly, without relying on live bacterial survival in the gut.

For Boxers specifically, three aspects of the Biotics Triad are directly relevant:

First, the prebiotic fraction supports the growth and activity of beneficial commensal bacteria that compete with pathobionts for mucosal attachment sites. A dense, diverse commensal community is one of the most important structural defences against AIEC colonisation: it reduces the ecological space available for invasive strains to establish a foothold.

Second, Bacillus velezensis DSM 15544 (Calsporin) contributes to microbiome diversity and gut-associated immune regulation, supporting the balance of regulatory and inflammatory immune activity in the colonic mucosa.

Third, postbiotics, including the structural components and metabolic products of beneficial bacteria, directly support tight junction integrity and mucosal barrier function in ways that do not depend on live bacteria surviving to the site of action. For a breed where mucosal barrier health is the primary line of defence against AIEC invasion, this direct mucosal support is meaningful.

Biotics is recommended for all Boxers as a daily supplement, regardless of whether the individual dog has a history of digestive problems.

Belly: For Boxers with Digestive Sensitivity

For Boxers who present with regular digestive sensitivity, including soft stools, flatulence, bloating, or a tendency to react to dietary changes, Belly is the appropriate secondary recommendation alongside Biotics.

Belly targets gut motility and mucosal support, addressing the practical digestive challenges that many Boxers experience on a day-to-day basis. It is relevant for owners managing the general gastrointestinal sensitivity picture beyond the specific clinical risk of HUC, and for those whose Boxer has a history of loose stools or gas.

Belly and Biotics work in complementary roles: Biotics as the microbiome and immune foundation, Belly as the motility and mucosal support layer for dogs whose digestive symptoms require additional targeted management.

Block: For Boxers with Immune-Reactive Skin or Allergy Signs

Some Boxers present with a combined gut-skin or gut-immune picture, where digestive sensitivity accompanies atopic skin signs, immune-reactive dermatitis, or food sensitivity with both cutaneous and gastrointestinal manifestations.

For this presentation, Block is the appropriate alternative secondary supplement alongside Biotics, replacing Belly rather than supplementing it. Block addresses the gut-skin-immune intersection, supporting the gut-skin axis that links mucosal immune regulation to skin barrier function and immune reactivity.

Block is positioned as an alternative lead for the gut-skin-immune presentation subgroup in Boxers, not as a stacking supplement. Owners should select Belly or Block based on their dog’s primary presentation, in consultation with their vet where signs are significant.

For a full explanation of the three-layer prebiotic, probiotic and postbiotic framework that underpins these recommendations, see Gut Health Supplements for Dogs: Why Probiotics Alone Are Not Enough.

---

How To Support Your Boxer’s Gut Health: A Practical Guide

---

Safety Considerations and When to See Your Vet

Biotics and Belly are food-grade, functional supplements designed for long-term use in healthy adult dogs. They are not veterinary medicines and are not intended to treat, cure, or prevent any disease. Always introduce new supplements gradually to allow the digestive system to adjust.

See your vet promptly if your Boxer shows any of the following:

• Bloody, mucoid, or persistently soft stools, particularly in dogs under four years of age
• Unexplained weight loss or reduced appetite
• Signs of abdominal discomfort, distension, or bloating
• Anaemia, lethargy, or pale gums
• Any new skin lumps or bumps, given the Boxer’s MCT predisposition

HUC is a serious condition that requires veterinary diagnosis and targeted antimicrobial treatment based on susceptibility profiling. It cannot be managed with dietary changes or supplements alone, and delay in diagnosis worsens prognosis. If a young Boxer presents with chronic large-bowel diarrhoea that is unresponsive to routine management, granulomatous colitis should be considered and colonoscopy with biopsy pursued rather than prolonged empirical treatment.

For any Boxer showing signs of abdominal bloating or distension combined with unproductive retching, seek emergency veterinary care immediately. Gastric dilatation-volvulus is a life-threatening emergency in deep-chested breeds and requires urgent surgical intervention.

---

Frequently Asked Questions

---

Conclusion

The Boxer’s gut health story is, at its core, a story about what happens when genetic susceptibility meets microbial opportunity. Histiocytic ulcerative colitis is not a random misfortune: it is the clinical expression of a specific failure in mucosal immune defence, exploited by a specific bacterial pathobiont that the Boxer’s immune architecture is less equipped than other breeds to contain. The resolution of decades of diagnostic uncertainty through the identification of AIEC as the causative organism was not merely a scientific advance; it was a shift in how we understand the relationship between the gut microbiome, the mucosal barrier, and breed-specific disease risk.

For Boxer owners, this science points to one clear conclusion: gut health is not a background variable to be addressed only when symptoms appear. It is a primary health priority, grounded in the same evidence that explains why HUC develops in the first place. A diverse, well-supported gut microbiome does not guarantee protection against HUC or against the Boxer’s cancer predisposition. But the conditions it creates, including robust colonisation resistance, intact mucosal barrier function, and well-regulated gut-associated immune activity, are precisely the conditions that make those risks less likely to express themselves at their worst. In a breed that carries as much clinical distinctiveness as the Boxer, that is an investment worth making every day.

---

Related Articles

• The Dog Gut Microbiome: Vital Key to Dog Health
• The Gut-Immune Axis in Dogs: How Gut Health Supports Immune Health
• The Gut-Longevity Axis in Dogs: Key To Improved Healthspan
• Best Probiotics for Dogs: Canine Nutritionist’s Guide to Real Gut Impact
• Best Prebiotics for Dogs: Canine Nutritionist’s Complete Guide
• Gut Health Supplements for Dogs: Why Probiotics Alone Are Not Enough
• Gut Dysbiosis in Dogs: Causes, Symptoms & How to Restore Balance
• Postbiotics for Dogs: Evidence-Based Guide to Health Benefits

---

References

1. Simpson KW, Dogan B, Rishniw M, Goldstein RE, Klaessig S, McDonough PL, German AJ, Yates RM, Russell DG, Johnson SE, Berg DE, Harel J, Bruant G, McDonough SP, Schukken YH. Adherent and invasive Escherichia coli is associated with granulomatous colitis in boxer dogs. Infect Immun. 2006;74(8):4778–92. doi: 10.1128/IAI.00067-06. PMID: 16861666. PMC: PMC1539603.
2. Mansfield CS, James FE, Craven M, Davies DR, O’Hara AJ, Nicholls PK, Dogan B, MacDonough SP, Simpson KW. Remission of histiocytic ulcerative colitis in Boxer dogs correlates with eradication of invasive intramucosal Escherichia coli. J Vet Intern Med. 2009;23(5):964–9. doi: 10.1111/j.1939-1676.2009.0363.x. PMID: 19678891.
3. Craven M, Mansfield CS, Simpson KW. Granulomatous colitis of boxer dogs. Vet Clin North Am Small Anim Pract. 2011;41(2):433–45. doi: 10.1016/j.cvsm.2011.01.003. PMID: 21486645.
4. Manchester AC, Hill S, Sabatino B, Armentano R, Carroll M, Kessler B, Miller M, Dogan B, McDonough SP, Simpson KW. Association between granulomatous colitis in French Bulldogs and invasive Escherichia coli and response to fluoroquinolone antimicrobials. J Vet Intern Med. 2013;27(1):56–61. doi: 10.1111/jvim.12020. PMID: 23206120.
5. Dogan B, Zhang S, Kalla SE, Dogan EI, Guo C, Ang CR, Simpson KW. Molecular and phenotypic characterization of Escherichia coli associated with granulomatous colitis of Boxer dogs. Antibiotics (Basel). 2020;9(9):540. doi: 10.3390/antibiotics9090540. PMID: 32854367. PMC: PMC7559917.
6. Manchester AC, Dogan B, Guo Y, Simpson KW. Escherichia coli-associated granulomatous colitis in dogs treated according to antimicrobial susceptibility profiling. J Vet Intern Med. 2021;35(1):150–161. doi: 10.1111/jvim.15995. PMID: 33321554. PMC: PMC7848323.
7. Smith CR, Miller AD. In situ hybridization to detect Escherichia coli in canine granulomatous colitis. J Vet Diagn Invest. 2024;36(1):142–145. doi: 10.1177/10406387231213358. PMID: 37968864. PMC: PMC10734575.
8. Shoop SJW, Marlow S, Church DB, English K, McGreevy PD, Stell AJ, Thomson PC, O’Neill DG, Brodbelt DC. Prevalence and risk factors for mast cell tumours in dogs in England. Canine Genet Epidemiol. 2015;2:1. doi: 10.1186/2052-6687-2-1. PMID: 26401329. PMC: PMC4579370.
9. Dobson JM. Breed-predispositions to cancer in pedigree dogs. ISRN Vet Sci. 2013;2013:941275. doi: 10.1155/2013/941275. PMID: 23738139. PMC: PMC3658424.
10. Pilla R, Suchodolski JS. The role of the canine gut microbiome and metabolome in health and gastrointestinal disease. Front Vet Sci. 2020;6:498. doi: 10.3389/fvets.2019.00498. PMID: 31993446. PMC: PMC6971114.

---

Editorial Information

Field	Detail
Published	March 2026
Last Updated	March 2026. This article is reviewed and updated when new peer-reviewed evidence becomes available.
Reviewed by	Veterinary Advisory Board
Next Review	March 2027
Author	Glendon Lloyd, Dip. Canine Nutrition (Dist.), Dip. Dog Nutrigenomics (Dist.), Founder, Bonza
Disclaimer	This article is for informational purposes only and does not constitute veterinary advice. Always consult a qualified veterinarian before making changes to your dog’s diet or supplement regimen.